Mercy Bioanalytics Inc. stepped into the increasingly competitive early cancer detection field with a $41 million series A financing round to support its Halo liquid biopsy platform. Novalis Lifesciences led the oversubscribed round with participation from Sozo Ventures, Hatteras Venture Partners, Iselect Fund, American Cancer Society BrightEdge and Broadway Angels, an all-women venture capital group. Laboratory Corp. of America Holdings, Bruker Corp. and existing investors also contributed to the round.

Adcendo ApS has added a further €31 million (US$33.6 million) to its series A round, providing the means to take its lead antibody-drug conjugate (ADC) through to clinical proof of concept in the treatment of sarcoma.

Biopharmas raising money in public or private financings, including: Cure Ventures, Diamond, Mosaic, OS Therapies, Psyence, Recce, Redhill, Viking.

Med-tech firms raising money in public or private financings, including: BBS, Bio-Techne, Mercy Bioanalytics, Wilson Wolf.

Biopharmas raising money in public or private financings, including: Addex, Palisade, Vaccinex.

Cancer treatment developer Apollomics Inc. merged with special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., gaining a listing on Nasdaq under the ticker APLM and raising $23.65 million of private investment in public equity (PIPE).

Med-tech firms raising money in public or private financings, including: Bioventus, G Medical Innovations, Wellth.

Biopharmas raising money in public or private financings, including: Alligator, Aptevo, Checkpoint, Medexus, Renovorx, TC, Xoma, Zealand.

Shoulder Innovations Inc. (SI) reported closing of an oversubscribed $42 million series D financing to further advance commercialization and distribution of its integrated Inset system. In addition to functions performed by SI’s humeral short stem, reverse and stemless components the new implant has proven its ability to overcome loosening of the glenoid, one the most challenging procedures to perform during arthroplasty.